Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pre-TURBT mitomycin C with TC-3 hydrogel in NMIBC
NL-OMON38450Phase 2Withdrawn
- Sponsor
- Sintesi Research
- Start
- Oct 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of mitomycin c in non-muscle-invasive bladder cancer (NMIBC) and transitional cell carcinoma of the bladder (TCC) (2 arms), sponsored by Sintesi Research. Primary endpoints: Cystoscopic and pathological effect at TURBT and Safety and adverse event rate. Planned start Oct 2013; status: withdrawn.
02
Drugs
mitomycin c
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)transitional cell carcinoma of the bladder (TCC)
Beyond the preview
Go deeper on NL-OMON38450.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38450.